Trending News

Neurons
#Dementia #Neurodegenerative disorders #Parkinson's #Peptides #University of Bath

Scientists design peptide ‘switch’ to slow Parkinson’s progress

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias.   The team has successfully demonstrated it works in an animal model… Read More

#News #Trending News

Monoclonal antibody
#Antibody #iBio #Obesity #Preclinical development #Weight loss

Twice-yearly antibody shows strong therapeutic potential for weight-loss

iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.  The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More

#News #Trending News

Patient injects Ozempic
#Diabetes #GLP-1 #Innovent #Phase III trial #Weight loss

Mazdutide shows superiority to semaglutide in a head-to-head trial

In the Phase III DREAMS-3 clinical trial of mazdutide, the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist showed superior efficacy to semaglutide for body weight reduction.  In Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide performed better than semaglutide on the primary endpoint,… Read More

#News #Trending News

Ozempic (semaglutide)
#Cardiovascular disease #GLP-1 #Novo Nordisk #University College London

Semaglutide protects heart beyond weight loss benefits

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, says a new study led by University College London (UCL).  The finding, the researchers say, suggests there are multiple ways the drug… Read More

#News #Trending News

#Cell therapy #Galapagos

Galapagos plans to end cell therapy efforts and close sites

Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture.  The move follows similar ones by Novo Nordisk and Takeda, which recently announced the decision to discontinue its cell therapy efforts, as part of a “strategic portfolio… Read More

#Business & Investment #News #Trending News

Cell and gene therapy
#Gene therapy #Genetics / genomics #Hearing Loss #Regeneron Pharmaceuticals

Gene therapy brings “new era” in the treatment of hearing loss

New gene therapy trial results have shown dramatic and sustained improvements in hearing and speech perception in children with profound genetic hearing loss.  The updated data for Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were… Read More

#News #Trending News

Neuron
#Gain Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Early data suggest GT-02287 slows Parkinson’s disease

Gain Therapeutics has shared early safety and tolerability findings, the primary endpoint, and observations from key exploratory endpoints from the Phase Ib clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation.  The findings were presented in a poster at the… Read More

#News #Trending News

Breast cancer
#Breast cancer #Eli Lilly #FDA #Gene mutation #Oncology

FDA approves Inluriyo in ER+, HER2-, ESR1-mutated breast cancer

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist.  It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after… Read More

#News #Regulatory #Trending News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News

#Association of the British Pharmaceutical Industry #Biopharmaceuticals #Pharmaceutical industry #UK government

UK pharma pricing discussions end in stalemate

The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme.  In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More

#News #Trending News

Human liver
#FDA #Fibrosis #GLP-1 #Liver disease #Novo Nordisk

Wegovy granted accelerated approval in the US for liver disease

The US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4mg) as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).  The approval is in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet… Read More

#News #Regulatory #Trending News

Woman standing on scales
#Adverse event #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Mixed top-line results for Viking’s oral obesity drug

Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.   VK2735 is being developed in both oral and subcutaneous formulations for… Read More

#News #Trending News

T cell attacking a cancer cell
#Antibodies #Immunotherapy #Oncology #Phase I trial #Rockefeller University

Immunotherapy drug eliminates aggressive cancers

A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.  CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.  … Read More

#Cancer Research #News #Trending News